Tofacitinib vs Adalimumab Findings Require Caution in RA - Summary - MDSpire
From the Journals

Tofacitinib vs Adalimumab Findings Require Caution in RA

Meta-analysis favored tofacitinib for some rheumatoid arthritis outcomes, but high heterogeneity, dose-dependent effects, and JAK inhibitor safety concerns complicate interpretation.

  • By

  • Andrea Surnit

  • May 8, 2026

  • 4 min

Share

A systematic review and meta-analysis published in Frontiers in Pharmacology indicates that tofacitinib offers greater efficacy in improving ACR20 outcomes compared to adalimumab in rheumatoid arthritis patients. The review analyzed data from nine studies, involving 24,643 patients, but cautioned regarding heterogeneity and long-term safety concerns associated with JAK inhibitors. Current guidelines recommend caution when using tofacitinib in patients with cardiovascular risks or prior malignancies, highlighting the need for larger studies to assess its comparative benefits and risks.

Original Source(s)

Tofacitinib vs Adalimumab Findings Require Caution in RA

  • by Andrea Surnit

  • May 8, 2026

Related Content

Serum Urate Goals Tied to Lower CV Risk

Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients

Lung Disease Complicates RA Care

Patients with chronic lung disease had numerically lower remission rates and substantially more serious adverse events in a 5-year Japanese registry study of late-onset rheumatoid arthritis.

Deep Remission Tied to RA Control

At 5 years, 63% of patients in the CliDR group maintained sustained remission compared with 38% in the non-CliDR group.